HS

[HS @Dr_Hazen]

@nunzi46 I think you mean this is the tricks VCs played on LPs

[HS @Dr_Hazen]

@arjunrajlab Nobody thinks that. Every “young scientist” understands that p-value is flawed and annoying.

But Academia is highly political and this is how the game is played.

[HS @Dr_Hazen]

@realEstateTrent The corporate world runs on Excel, PowerPoint, and Word. Outlook comes with the package.

[HS @Dr_Hazen]

@m_goes_distance Layer 5 is not always needed. Many drugs (especially small molecules) can be made selective only for the dysfunctional protein, so the drug can be distributed to all cells. It needs better drug design.

Still waiting for Isomorphic to bring their first drug to human testing.

[HS @Dr_Hazen]

@agupta Correct solution, but it will require massive public investment to meaningfully expand med student spots.

There is no lack of talented students aspiring to be doctors. But there is no private capital going into educating more doctors.

[HS @Dr_Hazen]

@PeterKolchinsky @jrkelly @navyadotbio This has been tested. Many LatAm countries mandate post-trial access as few pursue commercial launch. We commit to PTA even in countries where it is not required, just as an ethical factor.

No country is going to sustain a ban on their citizens from accessing clinical trials.

[HS @Dr_Hazen]

@theanantpai They think they will cure all cancers, but can’t even get email to work

[HS @Dr_Hazen]

@http_413 @peterottsjo Ok, perhaps a better comparison: do you think in 10 years we’ll eliminate all email outages?

[HS @Dr_Hazen]

@michellearning So if I got 10 citations on a paper last month, can I say my paper has 120 citations ARR?

[HS @Dr_Hazen]

@eperlste And by 1920 all of transportation was solved I guess.

[HS @Dr_Hazen]

@PeterKolchinsky @navyadotbio @jrkelly >what happens when China strikes a deal with Europe to provide it with inexpensive drugs for every class approved in the US but withheld from Europe by MFN

The Chinese biotechs will go bankrupt

[HS @Dr_Hazen]

@MichaelTontchev That you believe:
- Interacting with cells wouldn’t involve biochemical pathways
- Cellular mechanisms of disease are less complex than biochemical mechanisms
- Nanobots are magic

I do drug development and use AI for everything, but tech is just weird about bio nowadays

[HS @Dr_Hazen]

@Ben02015 @venikunche Covid is acute, you figure out very quickly if the vaccine worked or not.

The tough diseases are chronic. CV, Alzheimer’s, many cancers, etc. You have to measure patients for years before you can even tell if there is any difference.

[HS @Dr_Hazen]

@hosseeb And what is exactly is the point of the VC? If this is feasible, we should be getting close to the point where LPs can just skip the middle man.

[HS @Dr_Hazen]

@ExoExplorer3 @Banana_Oncology It’s the ‘10 years’ claim. If he said 25 years, there would be much less skepticism.

But to answer your question, today it is 1) The cure for all cancers is not going to be found by reading, reasoning, and simulation. It requires experiments in the real world.

[HS @Dr_Hazen]

@Biohazard3737 > eligibility for longer exclusivity

If longer exclusivity is on the table, then nothing else would matter. That would completely change the calculation of the price required for a drug to be worth developing.

[HS @Dr_Hazen]

@deedydas Exploiting the hopes of cancer patients and their families to pump an IPO is not admirable. Working in drug development / medicine and interacting with patients teaches you the massive information asymmetry.

This isn’t like software or EVs. The words affect real people.

[HS @Dr_Hazen]

@ZacB_MN Didn’t Warnock have some sketchy domestic issues with his ex-wife? I remember it came up when he first ran.